Missed it deep in the Application for Quotation notice.
As announced in the Appendix 3B released on 26 October 2023, 2,000,000 shares are proposed to be issued. The first tranche of 1,539,150 shares were issued on 2 November 2023. The second tranche was revised to 125,000 shares and it is now planned that the remaining 335,850 shares will be issued on or before 15 December 2023 with the intention to close as soon as possible.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-57
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.91 |
Change
0.000(0.00%) |
Mkt cap ! $91.59M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 857 | $5.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.08 | 260 | 1 |
View Market Depth
| Last trade - 07.00am 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable